– In a Phase 3 clinical study evaluating the efficacy and safety of sparsentan in Japanese patients with IgA nephropathy ...
Accsys Technologies PLC ( OTCPK:ACSYF) Q2 2026 Earnings Call November 25, 2025 4:00 AM EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback